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Megalencephalic leukoencephalopathy with subcortical cysts (MLCs) disease is a rare
inherited, autosomal recessive form of childhood-onset spongiform leukodystrophy
characterized by macrocephaly, deterioration of motor functions, epileptic seizures and
mental decline. Brain edema, subcortical fluid cysts, myelin and astrocyte vacuolation
are the histopathological hallmarks of MLC. Mutations in either the MLC1 gene
(>75% of patients) or the GlialCAM gene (<20% of patients) are responsible for the
disease. Recently, the GlialCAM adhesion protein was found essential for the membrane
expression and function of the chloride channel ClC-2 indicating MLC disease caused
by mutation in GlialCAM as the first channelopathy among leukodystrophies. On
the contrary, the function of MLC1 protein, which binds GlialCAM, its functional
relationship with ClC-2 and the molecular mechanisms underlying MLC1 mutation-
induced functional defects are not fully understood yet. The humanMLC1 gene encodes
a 377-amino acid membrane protein with eight predicted transmembrane domains
which shows very low homology with voltage-dependent potassium (K+) channel
subunits. The high expression of MLC1 in brain astrocytes contacting blood vessels
and meninges and brain alterations observed in MLC patients have led to hypothesize
a role for MLC1 in the regulation of ion and water homeostasis. Recent studies have
shown that MLC1 establishes structural and/or functional interactions with several
ion/water channels and transporters and ion channel accessory proteins, and that these
interactions are affected by MLC1 mutations causing MLC. Here, we review data on
MLC1 functional properties obtained in in vitro and in vivomodels and discuss evidence
linking the effects of MLC1 mutations to brain channelopathies.
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Introduction
Channelopathies are a heterogeneous group of disorders of genetic or acquired origin caused
by altered function of ion channel subunits or the proteins that regulate them. These include
diseases of the cardiovascular, muscular, respiratory, urinary, endocrine, and immune systems.
Due to the fundamental role played by ion channels in neuronal activity, channelopathies
are involved in a growing number of nervous system disorders (Kim, 2014 and references
therein). Channelopathies leading to dysfunction of astrocytes, the glial cells responsible for
the control of ion homeostasis in the central nervous system (CNS), have also been described
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(Wingerchuk et al., 2007; Vaknin-Dembinsky et al., 2014). The
rare leukodystrophy megalencephalic leukoencephalopathy with
subcortical cysts (MLC) has recently emerged as a potential
brain channelopathy associated to astrocyte dysfunction (Van der
Knaap et al., 2012; Lanciotti et al., 2013).
Leukodystrophies comprise a large number of rare genetic dis-
orders that aﬀect mainly the CNS with diﬀerent etiology and
a common target. The European Leukodystrophies Association
(ELA) oﬀers a classiﬁcation including the following types: perox-
isomal, lysosomal, vacuolating, hypomyelinating, atypical, unde-
termined. Against such a heterogeneous etiopathogenesis, the
common target is myelin: “either the myelin does not form,
degrades, or is too abundant” (from the oﬃcial ELA site:
http://ela-asso.com).
Leukodystrophies have an incidence of 1 in 7,663 live births
(Bonkowsky et al., 2010) and manifest themselves mostly dur-
ing childhood or adolescence. MLC disease, ﬁrst described in
1995, belongs to the childhood-onset vacuolating leukodystro-
phy group (Van der Knaap et al., 1995a,b, 1996; Singhal et al.,
1996). The incidence of MLC is unknown, although it seems to
be more frequent in countries surrounding the Mediterranean
basin and in the Indian Agarwal community (Topcu et al., 1998;
Ben-Zeev et al., 2002; Singhal et al., 2003). Clinically, MLC is
characterized by macrocephaly, deterioration of motor functions
with ataxia and spasticity, epileptic seizures and mental decline;
minor head trauma or common infections can lead to worsening
of clinical conditions often with seizures, prolonged unconscious-
ness and motor deterioration (Van der Knaap et al., 1995a,b,
1996; Singhal et al., 1996; Topcu et al., 1998; Bugiani et al.,
2003). Brain magnetic resonance imaging (MRI) shows diﬀuse
white matter swelling, subcortical cysts (mainly in the temporal
and fronto-parietal regions) and, in some patients, severe neu-
rodegeneration (Mejaski-Bosnjak et al., 1997). Analysis of brain
biopsies has revealed the presence of liquid vacuoles between the
outer lamellae of the myelin sheaths, suggesting defects in lamel-
lae compaction or their splitting along the intraperiod line (Van
der Knaap et al., 1996; Pascual-Castroviejo et al., 2005). Reactive
and stressed astrocytes with vacuoles and swelling in the end-
feet contacting blood vessels have also been observed (Van der
Knaap et al., 1996; López-Hernández et al., 2011b). Despite exten-
sive white matter damage, the disease phenotype is less severe
than in other leukodystrophies in which similar myelin vacuo-
lation is described (Van der Knaap et al., 2012; Lanciotti et al.,
2013).
The ﬁrst gene responsible for MLC was mapped to chro-
mosome 22qtel and identiﬁed as MLC1 (Topçu et al., 2000;
Leegwater et al., 2001). TheMLC1 gene consists of 12 exons with
an untranslated ﬁrst exon, spanning at least 24 kilobases (Steinke
et al., 2003). A broad spectrum of MLC1 pathogenic mutations
(>60, including missense, splice site, insertions and deletions)
have been identiﬁed in about 80% of aﬀected individuals (Boor
et al., 2006). Themutations are distributed along the wholeMLC1
protein sequence and show no clear correlation with the sever-
ity of the disease phenotype (Patrono et al., 2003; Montagna
et al., 2006). The MLC1 gene encodes a protein that is mainly
expressed in brain astrocytes, particularly at the astrocyte end-
feet contacting the blood–brain barrier and the pial membrane.
Recently, mutations in a second gene encoding the cell adhesion
protein GlialCAMhave been found in about 50% ofMLCpatients
not carrying mutations in MLC1 (<20% of the MLC-aﬀected
population; López-Hernández et al., 2011a). GlialCAM is highly
expressed in the liver and in the CNS, particularly in neurons and
glial cells, where it binds MLC1 (López-Hernández et al., 2011b).
The identiﬁcation of GlialCAM as the molecular chaperon and
functional modulator of the chloride channel ClC-2 (Jeworutzki
et al., 2014) has allowed for the ﬁrst time to explain the similar-
ities between brain alterations found in ClC-2 KO mice (Blanz
et al., 2007) and those characteristic of MLC patients. Notably,
this ﬁnding also led to identify MLC disease caused by mutations
in the GlialCAM gene as the ﬁrst leukodystrophy among brain
channelopathies. Although GlialCAMhas been initially identiﬁed
as the molecular chaperon transporting both MLC1 and ClC-
2 to the astrocyte plasma membrane, the relationship between
MLC1 and the ClC-2 channel is not fully understood yet. MLC1
protein structural features, molecular interactors (see below) and
brain alterations observed in MLC patients (edema, ﬂuid cysts,
astrocyte, and myelin vacuolation) suggest that MLC1 can play
a role in the regulation of ion and water ﬂuxes and cell volume.
However, although several recent studies support this hypothesis
(Ridder et al., 2011; Lanciotti et al., 2012; Brignone et al., 2014;
Hoegg-Beiler et al., 2014; Dubey et al., 2015), the exact function
of MLC1 is still unknown.
In this article we shall present and discuss data onMLC1 struc-
tural and functional properties obtained in diﬀerent experimen-
tal settings, suggesting a link between MLC1 mutation-induced
alterations in MLC disease and brain channelopathies.
The Puzzling MLC1 Protein:
Biochemical Features and Cellular
Localization
Molecular Structure and Post-Translational
Modifications
After the discovery of mutations in the MLC1 gene as the
main cause of MLC, several research groups have investigated
the physiological function of MLC1 with the aim of disclos-
ing the pathogenic mechanisms underlying the disease. This
has been a particularly challenging task. Analysis of the pri-
mary nucleotide sequence indicated that the human MLC1 gene
encodes a 377-amino acid highly hydrophobic protein contain-
ing eight predicted transmembrane domains and short amino-
and carboxylic- cytoplasmic tails (Figure 1; Meyer et al., 2001;
Teijido et al., 2004). MLC1 also contains an internal repeat struc-
ture resulting in a partial homology of the primary sequence
between the two halves of the protein that is also found in several
ion channels (Teijido et al., 2004). However, blast sequence anal-
ysis indicates that MLC1 has no similarities with known proteins,
with the exception of a very low homology with the shaker-related
voltage gated potassium (K+) channel Kv1.1 α subunit (less than
20% amino acid identity; Teijido et al., 2004).
Based on this knowledge, the ﬁrst studies aimed at identifying
the biochemical and structural features of MLC1 protein. Early
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FIGURE 1 | Schematic representation of specific amino acid consensus
motifs found in the human megalencephalic leukoencephalopathy with
subcortical cysts (MLC1) protein sequence. The picture shows consensus
motifs for post-translational modifications (glycosylation and phosphorylation),
protein–protein or protein–lipid interactions (protein dimerization and cav-1 and
cholesterol binding sites) and protein trafficking signals (endoplasmic reticulum
export and retention signals), either putative (empty circles), or functionally
identified (filled circles) (modified from Lanciotti et al., 2012).
experiments carried out in transiently transfected heterologous
cells (HeLa cells and Xenopus oocytes; Teijido et al., 2004), cul-
tured primary rat astrocytes and rat brain tissue (Teijido et al.,
2004; Ambrosini et al., 2008) showed that MLC1 is a 36–40 kDa
protein that is able to form highly stable dimeric and oligomeric
structures (mainly dimers but also tetramers). By performing
subcellular fractionations of rat astrocytes and brain tissue it was
found that the MLC1 monomeric form is present only in the
cytosolic fraction (mainly organelle fraction) while the dimers are
associated with the membrane compartments (plasmamembrane
and endoplasmic reticulum membranes; Ambrosini et al., 2008;
Lanciotti et al., 2010). Database analysis of the MLC1 primary
sequence revealed potential post-translational modiﬁcation sites,
including phosphorylation and glycosylation sites (Figure 1).
However, the results of endoglycosydase treatment and site-
directed mutagenesis of the putative glycosylation site (NPS in
the second extracellular loop, Figure 1) ruled out that MLC1 is
glycosylated when expressed in heterologous cells (Teijido et al.,
2004), but did not allow to exclude that the endogenous pro-
tein is glycosylated in astrocytes. In vitro studies on recombinant
peptides and endogenous protein from rat astrocytes indicated
that MLC1 is phosphorylated at its NH2 and COOH terminals
by both PKA and PKC and PKC alone, respectively (Lanciotti
et al., 2010; Figure 1). Furthermore, it was found that treat-
ment with substances activating PKC or PKA and phosphatase
inhibitors (forskolin, okadaic acid, phorbol esters, genistein) can
modify MLC1 plasma membrane expression and formation of
multimeric structures (Lanciotti et al., 2010). Interestingly, anal-
ysis of the MLC1 aminoacidic sequence revealed the presence of
an arginine-based ER retention motif RXR (Schutze et al., 1994;
Michelsen et al., 2005) localized in the NH2 terminal near the
PKC and PKA phosphorylation sites (Figure 1). Changes in the
extent of phosphorylation at sites adjacent to the RXR-type ER
retention motif may enable a given protein to interact with the
forward secretory machinery by hiding or hampering the reten-
tion signals, therefore allowing channel/receptor traﬃcking to the
plasma membrane (Scott et al., 2003). The ability of intracellu-
lar signaling to modulate ER export of RXR-containing protein
deﬁnes a regulatory pathway that may provide dynamic control
over the assembly and surface expression of a wide range of ion
channels and receptors (Shikano and Li, 2003). Our data indi-
cating that PKC and PKA activation favors MLC1 expression in
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the plasma membrane and the presence of an ER retention motif
near the PKC/PKA phosphorylation sites suggest this possibility
also for the MLC1 protein. The regulation of MLC1 membrane
localization (and also activity) by PKA and PKC phosphorylation
has been demonstrated for several ion channels and transporters.
For example, PKA activation enhances the forward traﬃcking of
the cystic ﬁbrosis transmembrane conductance regulator (CFTR;
Chang et al., 2002). PKA and PKC promote the translocation to
the apical membrane and activity of the transient receptor poten-
tial vanilloid-4 cation channel (TRPV4; Mamenko et al., 2013)
and PKA and PKC have an additive eﬀect in regulating the sur-
face expression of the Na, K-ATPase pump (Kristensen et al.,
2003). Protein kinases could also indirectly regulate MLC1 export
toward the plasma membrane by their involvement in the for-
mation of coat protein II (COPII)-coated vesicles (Farhan et al.,
2010). The COPII protein complex forms transport vesicles from
the ER and, by binding speciﬁc diacidic motifs present in the C
terminal of the cargo protein, incorporates it into these vesicles
(Barlowe, 2003). The presence of the canonical COPII binding
motif DXE in the COOH terminal of theMLC1protein (Figure 1)
suggests that the same regulation takes place for MLC1, simi-
larly to what observed for some ion channels and transporters
(Wang et al., 2004; Sivaprasadarao et al., 2007; Zhang et al.,
2011). The presence of several additional putative phosphoryla-
tion sites in the MLC1 sequence, as reported in speciﬁc databases
(NetPhos 2 Server, Technical University of Denmark; Figure 1),
and the identiﬁcation by LC-MS analysis of several kinases and
phosphatases among MLC1 interactors in primary rat astrocytes
(Table 1; Ambrosini manuscript in preparation) suggest a more
complex phosphorylation-mediated regulation of MLC1 localiza-
tion, and probably function, in astrocytes. Experiments are in
progress in our laboratory to better understand the role of kinases
in MLC1 protein stability, molecular interactions, and function.
This knowledge could be relevant for the therapy of MLC since
several kinases are currently under investigation as drug targets
to modulate the activity of ion channels involved in tumoral,
inﬂammatory, and neurologic diseases (Son et al., 2013).
MLC1 Expression in Mouse and Human
Brain
One of the few certainties on MLC1 protein is its predominant
expression in brain astrocytes, particularly in astrocytic end-feet
contacting cerebral blood vessels. Due to this ﬁnding, MLC1
is emerging as a promising marker for perivascular astrocytes
(Masaki et al., 2012). The ﬁrst evidence of MLC1 expression in
glial cells came from an in situ hybridization study in rat brain
showing that MLC1 mRNA is mainly expressed in multipotent
neural precursor cells during the pre- and peri-natal period, and
in astrocytes, Bergmann glia, and ependymal cells, but not oligo-
dendrocytes and neurons, in the adult brain (Schmitt et al., 2003).
These researchers also found that MLC1 is developmentally reg-
ulated in the mouse brain, being maximally expressed at day 5
after birth and then decreasing to a lower and stable level from
post-natal day 7 to adulthood. More recently, the temporal cor-
respondence between the expression of MLC1 in human and
mouse brain has been demonstrated (Dubey et al., 2015). Using
speciﬁc antibodies, MLC1 protein was found predominantly in
TABLE 1 | Newly identified megalencephalic leukoencephalopathy with
subcortical cyst (MLC1) molecular interactors.
Kinases and phosphatases Accession
number
Serine/threonine-protein kinase mTOR P42346
Integrin-linked protein kinase Q99J82
cAMP-dependent protein kinase catalytic subunit alpha P27791
Cell division protein kinase 4 P35426
Casein kinase II subunit alpha P19139
Casein kinase II subunit beta P67874
Serine/threonine-protein phosphatase PP1-alpha catalytic subunit P62138
Serine/threonine-protein phosphatase 2A catalytic subunit alpha
isoform
P63331
Serine/threonine-protein phosphatase PP1 isozyme 1 P30366
Tyrosine-protein phosphatase non-receptor type 9 Q641Z2
Tyrosine-protein phosphatase non-receptor type 1 P20417
Serine/threonine-protein phosphatase 2A 55 kDa regulatory
subunit B alpha isoform
P36876
Tyrosine-protein phosphatase non-receptor type 6 P81718
Serine/threonine-protein phosphatase PP2A-1 catalytic subunit Q07099
Receptor-type tyrosine-protein phosphatase C P04157
Receptor-type tyrosine-protein phosphatase alpha Q03348
Receptor-type tyrosine-protein phosphatase zeta Q62656
Ion channel/transporter proteins
Voltage-dependent anion-selective channel protein 1 Q9Z2L0
Voltage-dependent anion-selective channel protein 2 P81155
Voltage-dependent anion-selective channel protein 3 Q9R1Z0
Chloride intracellular channel protein 4 Q9Z0W7
Excitatory amino acid transporter 1 P24942
This table lists some of the newly identified MLC1 interactors among
kinase/phosphatase and ion channel/transporter proteins (Ambrosini manuscript
in preparation). Interactors were identified by pull-down and LC-MS analysis of
primary rat astrocytes. Validation experiments are ongoing.
astrocyte compartments contacting the brain barriers, such as the
astrocyte end-feet contacting blood vessels, the meninges (pial
membrane) and ependymal cells lining the ventricles, and in
Bergmann glia in the cerebellum, but not in neurons, oligoden-
drocytes, microglia, and endothelial cells (Teijido et al., 2004;
Boor et al., 2005, 2007; Ambrosini et al., 2008). Outside the
CNS, MLC1 is expressed in blood cells, like lymphocytes, mono-
cytes, and macrophages diﬀerentiating in vitro (Boor et al., 2006;
Petrini et al., 2013). Accordingly, defects in hyposmosis-induced
Ca2+ inﬂux (see below) were recorded in monocyte-derived
macrophages from MLC patients, though the impact of such
alterations is unknown since MLC patients do not show overt
deﬁcits in blood or immune system functions.
Intracellular Distribution and Trafficking of
MLC1 Protein in Astrocytes
Biochemical studies in cultured astrocytes and rat brain tissue
showed that MLC1 is present in specialized areas of the plasma
membrane called lipid rafts (Lanciotti et al., 2010). Lipid rafts
are microdomains of the plasma membrane formed by a tightly
ordered lipid phase that is enriched in sterols (including choles-
terol), sphingolipids (including gangliosides) and phospholipids
with saturated hydrocarbon chains (Wang and Paller, 2006).
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Lipid rafts are deﬁned by resistance to extraction with non-
ionic detergents and low density in sucrose gradients. These
microdomains are highly dynamic and possess considerable lat-
eral mobility within the loosely ordered membrane. Caveolar
rafts containing caveolae, stable ﬂask-shaped invaginations of the
plasma membrane, are a subtype of lipid rafts highly enriched in
cholesterol and coated by caveolin-1 (cav-1). Cav-1, a hairpin-like
palmitoylated structural protein, is thought to stabilize the invagi-
nated caveolar structure. Caveolae have been described in sev-
eral cell types, including astrocytes and astrocytoma/glioma cells
(Zschocke et al., 2005; González et al., 2007), and are involved
in protein traﬃcking and formation of cell signaling complexes
(Simons and Ikonen, 1997; Brown, 2006). By performing lipid
raft separation by sucrose gradient, we found that only the MLC1
dimers are distributed in the membrane caveolar raft fraction,
both in cultured astrocytes and in rat brain tissue (Ambrosini
et al., 2008; Lanciotti et al., 2010; Figure 2). Presence of MLC1
protein in caveolar rafts is supported by binding of cav-1 to the
NH2 intracellular terminal of the MLC1 protein containing the
putative caveolin/cholesterol binding site (Lanciotti et al., 2010;
Figure 1).
Because MLC1 function is still unknown, we do not
understand at present the functional consequences of MLC1
localization in caveolar rafts. However, we have found that
cholesterol and agents modulating caveolae-dependent endo-
cytosis inﬂuence MLC1 transport from the plasma membrane
to the intracellular compartments (Lanciotti et al., 2010). Our
studies demonstrated that in astrocytes exposed to hyposmotic
stress MLC1 is translocated to the plasma membrane and
then internalized by caveolar endocytosis to be sorted to recy-
cling or degradation pathways (Figure 3). By cell fractionation,
immunoﬂuorescence and electron microscopy analysis of rat pri-
mary astrocytes and human astrocytoma cells, MLC1 protein was
detected in early endosomes (EEA1+ and Rab5+; Figures 3 and
FIGURE 2 | Association of MLC1 with detergent resistant membrane
(DRM)/lipid raft cell compartments. WB analysis of cholesterol-rich (triton
insoluble fractions: 3–6) and cholesterol-poor membrane fractions (triton
soluble fractions: 10–12) of WT MLC1 expressing U251 cells. The 60–64 kDa
MLC1 component is associated with the DRM fractions, whereas the 30 kDa
band is detected only in the soluble fractions together with a portion of the
60–64 kDa component. The same membrane was blotted with anti-caveolin-1
antibody to track the position of caveolae-enriched membranes in the DRM
fractions.
4A,B; Lanciotti et al., 2010; Brignone et al., 2014) and in Lamp-
1+ organelles and multivesicular bodies (Figure 4C; Lanciotti
et al., 2010; Brignone et al., 2014), but not, or at very low lev-
els in Golgi apparatus and clathrin vesicles (Lanciotti et al.,
2010). More recently, we found that in unstimulated astrocytes
MLC1 is abundantly expressed in the Rab11+ perinuclear stor-
age/recycling compartment from which it is recruited back to
the plasma membrane when cells are exposed to hyposmotic
stress (Figure 3; Brignone et al., 2014). Cytoskeletal elements
are involved in MLC1 intracellular traﬃcking since nocoda-
zole treatment, which perturbs microtubule organization, ham-
pers MLC1 accumulation in the Rab11+ endosomal recycling
compartment in rat primary astrocytes (Lanciotti et al., 2010).
It has been shown that stabilization of MLC1 in the plasma
membrane of rat astrocytes cultured for 3 weeks in the pres-
ence of the antimitotic cytosine arabinoside, which leads to
astrocyte maturation/diﬀerentiation, depends on intact actin ﬁl-
aments, but not microtubules or intermediate ﬁlaments (Duarri
et al., 2011). In this context, post-translational modiﬁcations can
exert an important role in MLC1 forward traﬃcking and sta-
bilization in the plasma membrane (see above). Overall, these
results provide evidence that the membrane expression level of
MLC1 is spatially and temporally regulated by agents modulat-
ing intracellular traﬃcking, cytoskeletal organization and lipid
composition of the plasma membrane, as observed for many
ion channels and transporters (Dart, 2010; Curran and Mohler,
2014).
MLC1 Molecular Interactors
One of the ﬁrst steps to disclose the function of a novel protein is
the identiﬁcation of its molecular interactors, which can provide
information on the biochemical pathways in which the protein of
interest is involved (Table 2). By using this approach, GlialCAM
has been identiﬁed as the second MLC disease-associated gene
and the molecular chaperon that targets MLC1 to astrocyte
cell–cell junctions (López-Hernández et al., 2011a,b; Capdevila-
Nortes et al., 2013).
Recently, new ﬁndings obtained in knock-out (KO) ani-
mal models have allowed to better understand the relationship
between GlialCAM and MLC1 in vivo (see below). As this article
focuses on the role of MLC1 protein, we refer the reader to spe-
ciﬁc publications for detailed studies on GlialCAM involvement
in MLC disease (López-Hernández et al., 2011a,b; Capdevila-
Nortes et al., 2013).
Dystrophin–Dystroglycan Complex and
Junctional Proteins
The observation that MLC disease shares some pathological
features with congenital muscular dystrophies with brain involve-
ment caused by mutations in proteins of the dystroglycan (DG)
associated protein complex dystrophin–dystroglycan complex
(DGC; Boor et al., 2007) prompted us and other research groups
to investigate the relationship between MLC1 and DGC. The
DGC is a multiprotein complex highly expressed in astrocyte
end-feet where it stabilizes ion and water channels, like the
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FIGURE 3 | Modeling of MLC1 intracellular trafficking. Our previous results indicated that MLC1 is internalized via caveolae-mediated endocytosis and traffics
through Rab5+ and EEA1+ early endosomes where it is sorted to the recycling (Rab11+ ) or degradative pathway (Lamp-1+ ; Lanciotti et al., 2010; Brignone et al.,
2014) (modified from Brignone et al., 2014).
FIGURE 4 | Ultrastructural analysis of endogenous MLC1 localization in
early endosome compartment (EEA1+ and Rab5+ organelles) and in a
multivesicular body. Electron microscopy analysis of ultracentrifuged cytosolic
protein fractions obtained from cultured rat astrocytes was performed using
anti-MLC1 Ab (10 nm gold particles) in combination with anti-EEA1 or anti-Rab5
Abs (5 nm gold particles). (A) MLC1 (black arrows) is localized in Rab5+
organelles (arrowheads) (B) MLC1 is localized in the membrane and intraluminal
areas (black arrows) of EEA1+ organelles (arrowheads). (C) MLC1
immunostaining in the membrane (arrowheads) and intracellular vesicles (black
arrows) of a multivesicular body-like structure. Scale Bars: 200 μm.
inward rectiﬁer potassium 4.1 (Kir4.1) channel and the water
channel aquaporin-4 (AQP4; Noell et al., 2011). It has been
shown that in the human brain MLC1 co-localizes with DGC
proteins, like α/β-DG, syntrophin and agrin, in astrocyte end-
feet contacting blood vessels (Boor et al., 2007; Ambrosini et al.,
2008). Moreover, in brain tissue from a patient with MLC
some components of the DGC (Kir4.1, agrin, and α-DG) are
mislocalized while others (merosin, β-DG and AQP4) retain
their normal perivascular localization (Boor et al., 2007). These
results appeared of interest since agrin and α-DG are speciﬁcally
involved in Kir4.1 clustering in the glial cell plasma membrane
(Noël et al., 2005) and deletion of the Kir4.1 gene in mice causes
myelin vacuolation and cyst formation that are reminiscent of
the MLC phenotype (Neusch et al., 2001). The MLC1/DGC
protein interaction was also supported by biochemical exper-
iments showing that Kir4.1 and MLC1 co-immunoprecipitate
in human brain (Boor et al., 2007) and that MLC1 is detected
among DGC complex proteins in cultured rat and human astro-
cytes (Boor et al., 2007; Ambrosini et al., 2008; Lanciotti et al.,
2010). In contrast with these data, electron microscopy showed
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FIGURE 5 | Schematic representation of MLC1 molecular interactions in perivascular astrocytes.
that MLC1 co-localizes with the zonula occludens protein-1
(ZO-1), a protein present in astrocyte–astrocyte junctions, but
not with β-DG in astrocyte end-feet contacting cerebrovascular
endothelial cells in the normal human adult cerebellum (Duarri
et al., 2011; Figure 5). The same study reports that MLC1
does not co-immunoprecipitate with DGC components in cul-
tured rat astrocytes acquiring a diﬀerentiated morphology upon
prolonged treatment with cytosine arabinoside (Duarri et al.,
2011). Diﬀerences in MLC1 molecular interactions in diﬀerent
brain regions (cerebral cortex versus cerebellum) and/or astro-
cyte developmental stages (proliferating neonatal rat astrocytes
versus mature diﬀerentiated astrocytes) could account for these
discrepancies. Interestingly, the DGC itself is also involved in
the organization and maintenance of junctional complexes dur-
ing brain development (Nico et al., 2003, 2004; Sjö et al., 2005).
Further studies are needed to clarify the issue of MLC1/DGC
relationship.
MLC1 Molecular Interactors Involved in
Osmoregulation and pH Control
Consistent with the hypothesis that MLC1 plays a role
in astrocyte-mediated osmoregulation, the MLC1 molecular
interactors we identiﬁed in preliminary studies included ion
channels and accessory proteins that are enriched in astrocyte
end-feet (Table 2). Using complementary biochemical, proteomic
and in vivo protein interaction assays (like pull-down, yeast two-
hybrid system assays, His co-fractionation associated to LC-MS
analysis and ouabain aﬃnity chromatography) in cultured rat
astrocytes and human astrocytoma cells, we found that MLC1
binds the β1 subunit of the Na, K-ATPase enzyme (Brignone
et al., 2011). We also showed that MLC1 is part of a multiprotein
complex comprising Kir4.1, cav-1, TRPV4, AQP4, syntrophin,
and the vacuolar ATPase (V-ATPase) and is involved in the
regulation of ion transport, cellular volume changes and intraor-
ganelle pH control (Brignone et al., 2011, 2014; Lanciotti et al.,
2012). We have found that other ion channels/transporters inter-
act with MLC1, such as the chloride intracellular channel 4
(CLIC4), the voltage-dependent mitochondrial anion channels
(VDAC1-3) and the excitatory amino acid transporter 1 (EAAT1;
Table 1). The functional relationship of these molecules with
MLC1 is under investigation. Cell fractionation and immunolo-
calization experiments revealed that in astrocytes MLC1 inter-
action with Na, K-ATPase and V-ATPase occurs mainly in the
membrane of intracellular organelles, like early and recycling
endosomes, in basal culture conditions and also in the plasma
membrane after exposure to osmotic stress (Brignone et al.,
2011, 2014). These results indicate that macromolecular com-
plexes comprising MLC1 may modulate the astrocyte response
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TABLE 2 | List of described MLC1 molecular interactors in astrocytes.
Experimental techniques Interaction
compartment
Experimental models Reference
GlialCAM Quantitative proteomic analysis and
quantitative mass spectrometry; in situ
hybridization and immunohistochemistry
(IHC); immunofluorescence (IF); electron
microscopy (EM) immunostaining
Membrane (COOH) Primary rat astrocytes; HeLa cells
Mlc1 (−/−) zebrafish
Mlc1 (−/−) mice
Human brain tissue
López-Hernández et al.
(2011a,b), Capdevila-Nortes
et al. (2013), Arnedo et al.
(2014a,b), Barrallo-Gimeno and
Estévez (2014), Sirisi et al.
(2014), Dubey et al. (2015)
Na,K-ATPase
beta1
Yeast two-hybrid assay; Ouabain-affinity
chromatography; Co-purification of
His-tagged proteins and LC–MS analysis;
IF; IHC
Membrane/cytosol
(NH2 )
Rat astrocytes and rat brain; human
astrocytoma cells
Brignone et al. (2011), Brignone
et al. (2014), Lanciotti et al.
(2012)
TRPV4 Pull-down assay; ouabain-affinity
chromatography.
Membrane Rat astrocytes; human astrocytoma
cells
Lanciotti et al. (2012), Brignone
et al. (2014)
V-ATPase Co-purification of His-tagged proteins and
LC-MS analysis; IF; IHC
Cytosol Rat primary astrocytes; human
astrocytoma cells; human brain
tissue
Brignone et al. (2014)
DGC complex IF; IHC; immunoprecipitation (IP);
Co-purification of His-tagged proteins and
co-fractionation assays; ouabain-affinity
chromatography
Membrane/cytosol Gliotic brain tissue; glioblastoma
tissue and brain tissue from an MLC
patient; human and rat astrocytes;
rat brain extracts; human
astrocytoma cells
Boor et al. (2007), Lanciotti
et al. (2010, 2012), Brignone
et al. (2011)
ZO-1 EM immunostaining; IP Membrane Rat and human brain Duarri et al. (2011)
Kir4.1 IP; co-purification of His-tagged proteins
and co-fractionation assays; ouabain-affinity
chromatography; IF; IHC
Membrane Human and rat astrocytes; rat brain
extracts; human astrocytoma cells
Boor et al. (2007), Lanciotti
et al. (2010, 2012), Brignone
et al. (2011), Dubey et al. (2015)
Cav-1 Pull-down assay; co-purification of
his-tagged proteins; IF
Membrane
(NH2; COOH)
Rat astrocytes; human astrocytoma
cells
Lanciotti et al. (2010)
ClC2 IHC; EM Mlc1-null mice Hoegg-Beiler et al. (2014),
Dubey et al. (2015)
to osmotic imbalance by spatially operating in the plasma mem-
brane and in intracellular membranes, similarly to what observed
for protein complexes linked to Ca2+, K+, and Cl− channels
(Babcock and Li, 2013; Venkatachalam et al., 2014). A more sys-
tematic evaluation of the function and mutation-induced alter-
ations of MLC1 in diﬀerent membrane compartments should be
pursued also in view of possible therapeutic applications. In fact,
there is increasing evidence that pharmacological treatments can
diﬀerently target ion channel and transporter protein complexes
in the plasmamembrane or intracellular compartments (Babcock
and Li, 2013).
Deciphering MLC Pathogenesis: From
Cellular to Animal Models
To shed light on MLC1 function and its role in MLC patho-
genesis, in the last years diﬀerent in vitro and in vivo patholog-
ical models have been developed. In vitro MLC disease mod-
els were set up by overexpressing WT and mutated MLC1 in
heterologous cells and astrocytes or by knocking-down MLC1
in astrocytes. Earlier studies performed in heterologous cells
(HeLa cells, HEK293 cells, Xenopus oocytes) expressing mutated
MLC1 protein showed that many missense pathological muta-
tions impaired MLC1 translocation to the plasma membrane.
MLC1 mutations also aﬀected the protein half-life by caus-
ing an increase in protein degradation (Teijido et al., 2004;
Duarri et al., 2008). This eﬀect was mainly ascribed to protein
misfolding problems and activation of the endoplasmic reticulum
associated degradation pathway (ERAD) since ERAD inhibitors
could block MLC1 degradation. After the discovery that cultured
astrocytes express MLC1 protein (Ambrosini et al., 2008), these
cells became the most relevant in vitro model to study MLC1
pathophysiology. Interestingly, some MLC1 mutations behave
diﬀerently when overexpressed in rat astrocytes compared to het-
erologous cells (Duarri et al., 2008), highlighting the need to
investigate MLC1 mutation-induced phenotypes in an astrocyte
background. To this end, we selected human astrocytoma cells
(U251 cells), since these cells express almost undetectable lev-
els of endogenous MLC1 protein. We therefore generated U251
cell lines stably expressing MLC1 WT or carrying some of the
several missense mutations found in MLC patients (Brignone
et al., 2011). The obtained astrocytoma cell lines expressed MLC1
at levels comparable to those detected in primary rat astro-
cytes.
Using U251 cell lines expressing diﬀerent MLC1 patholog-
ical mutations (i.e., S426R, S280L, and C125R) we found that
not all the mutated proteins were retained in the ER. For exam-
ple, MLC1 protein carrying the S426R mutation was able to
reach the plasma membrane, similarly to WT MLC1 (Brignone
et al., 2011). This result suggested that in vitro modeling of
MLC1 pathological mutations could unravel MLC1 mutation-
speciﬁc functional defects and eventually prove useful for testing
patient-tailored therapies. Using this system, we also found that
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the analyzed missense mutations altered the interaction of MLC1
with some previously identiﬁed interactors, such as GlialCAM,
Kir4.1, Na, K-ATPase, V-ATPase, and TRPV4 channel (Brignone
et al., 2011; Lanciotti et al., 2012), supporting further the func-
tional involvement of MLC1 in this macromolecular complex.
Interestingly, downregulation of MLC1 in primary rat astrocytes
by small interfering RNA (siRNA) silencing induced astrocyte
vacuolation, a pathological feature found in the MLC-aﬀected
brain (Duarri et al., 2011) and in mlc1-null mice (Dubey et al.,
2015), but did not alter the localization of the MLC1 interactor
ZO-1 (Duarri et al., 2011). Collectively, these results indicate that
in vitromodeling of MLC disease can, at least in part, recapitulate
MLC1 dysfunction.
Two diﬀerent mouse models have been recently developed in
which MLC1 has been constitutively knocked-down in all tis-
sues (Hoegg-Beiler et al., 2014; Dubey et al., 2015). A zebraﬁsh
model has also been generated by deleting the MLC1 ortholog
gene (Sirisi et al., 2014). MLC1-null mice recapitulate some
features of the human MLC disease, such as early-onset mega-
lencephaly and augmented brain water content, with appearance
of aberrant astrocytic processes adjacent to ﬂuid/brain barri-
ers and progressive white matter vacuolization. However, both
KO mice do not develop motor disabilities (even at later stages
of life) or brain cysts that are characteristic of the human dis-
ease. In general, when neuropathological hallmarks were com-
pared, brain lesions in MLC1-null mice were less severe than
those in MLC-aﬀected brain and zebraﬁsh lesions were even
less pronounced than mice lesions, predicting interspecies dif-
ferences, or occurrence of compensatory mechanisms in KO
animals. Analysis of mlc1-null mice revealed that, contrary
to what was found in vitro (López-Hernández et al., 2011b),
MLC1 is important for the correct localization of GlialCAM
and ClC-2 in astrocytes. It has been shown that MLC1 also acts
in trans, by inﬂuencing GlialCAM expression in oligodendro-
cytes which are devoid of MLC1 (Hoegg-Beiler et al., 2014).
On the contrary, lack of MLC1 does not aﬀect the distribu-
tion of α/β-DG, agrin, Na, K-ATPase, TRPV4, and ZO-1 in
astrocyte perivascular end-feet (Dubey et al., 2015). Evidence
supporting the importance of MLC1 for the correct localiza-
tion of GlialCAM and ClC-2 was also obtained in cultured
astrocytes derived from mlc1-null mice that were exposed to a
high extracellular K+ concentration mimicking neuronal activ-
ity (Hoegg-Beiler et al., 2014; Sirisi et al., 2014). However,
immunohistochemical analysis of brain sections from a MLC
patient carrying a missense mutation (S69L) leading to MLC1
downregulation showed no apparent abnormalities in GlialCAM
localization in perivascular astrocytes (López-Hernández et al.,
2011b); in the same patient GlialCAMmislocalization was found
restricted to the Bergman glia in the cerebellum (Sirisi et al.,
2014).
Although KO animal models do not completely recapitulate
the human disease, they conﬁrm that astrocyte-mediated defects
in water ﬂuxes and cell volume regulation are involved in MLC
disease pathogenesis, as suggested by results in in vitro mod-
els. Overall these ﬁndings indicate that the experimental models
used to study MLC1 function and MLC disease pathogenesis
can provide diﬀerent (sometimes contradictory) results. Some
discrepancies may reﬂect the inability of the in vitro systems to
reproduce the complexity of astrocyte functional and structural
connections in vivo. It is generally accepted that gene inactivation
in vivo represents an essential approach to study the physiologi-
cal roles of several proteins. However, KO mice, while useful for
a rough characterization of gene function, have some disadvan-
tages for deciphering precisely pathogenetic mechanisms, includ-
ing gene redundancy, and developmental issues. Furthermore,
not all the MLC1 mutations analyzed in vitro lead to complete
protein degradation, a phenotype recapitulated by null-mouse
models. Noteworthy, astrocytes display heterogeneous character-
istics depending on species of origin, brain region, developmental
stage, environmental factors, and disease states, all of which may
render experimental results highly variable. The complexity of the
glia themselves as well as the marked increase in the ratio of glia
to neurons in higher mammals (Pfrieger, 2009) suggest that some
roles of glia studied in mouse models might be non conserved
or even more critical in primates and humans (Molofsky et al.,
2012). For these reasons, advantages and disadvantages of each
experimental system should be taken into account for a correct
evaluation of the results obtained.
Astrocyte Functional Pathways
Affected by MLC1 Mutations
Regulation of Ca2+ Influx
Intracellular Ca2+ changes participate in the regulation of regu-
latory volume decrease (RVD) that occurs after cell swelling in
astrocytes. It has been shown that the cation channel TRPV4 co-
localizes with AQP4 in the astrocyte end-feet and is responsible
for an outward-rectifying Ca2+ conductance and Ca2+ inﬂux fol-
lowing cell swelling induced by mechanical and osmotic stress
(Benfenati et al., 2007, 2011; Figure 5). The TRPV4-mediated
Ca2+ inﬂux is an essential step in the activation of RVD in
astrocytes which is needed to rescue the temporary cell swelling
induced by hyposmosis. Using the U251 astrocytoma cell model,
we found that MLC1 mutations causing retention of the pro-
tein in the cytoplasmic perinuclear area aﬀect TRPV4-mediated
Ca2+ inﬂux induced by hyposmotic stress (Lanciotti et al., 2012).
This ﬁnding supports the hypothesis that MLC1 localized in the
plasmamembrane can functionally cooperate with TRPV4 to reg-
ulate Ca2+ inﬂux and RVD after osmotic imbalance. Moreover, as
in primary astrocytes (Benfenati et al., 2007, 2011), also in astro-
cytoma cells hyposmotic stress induces heterogeneous Ca2+ tran-
sients that diﬀer for lag time of onset, proﬁle of the transient (i.e.,
peak shaped, sustained, or a combination of the two) and maxi-
mal amplitude of the Ca2+ changes (Lanciotti et al., 2012). The
high variability in the Ca2+ response is hardly compatible with
a direct eﬀect of swelling on TRPV4 channels, but more likely is
the result of an indirect eﬀect mediated by a diﬀerent molecular
sensor (Christensen and Corey, 2007). The TRPV4 cation chan-
nel is known as a polymodal transducer of mechanical stretch,
osmotic pressure, and warmth perception (Nilius and Voets,
2013). However, it is debated whether TRPV4 is itself sensitive
to such stimuli or lies downstream of an osmotic sensor and only
mediates the transduction of the stimulus. The available evidence
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indicates that TRPV4 can be activated by second messengers and
phosphorylations (Xu et al., 2003; Poole et al., 2013). It has been
shown that activation of TRPV4 depends on phosphorylation on
tyrosine 253 by Src kinase or on 5,6′-epoxyeicosatrienoic acid
(5,6′-EET) resulting from the breakdown of arachidonic acid by
cytochrome P450 epoxygenase (Xu et al., 2003; Poole et al., 2013).
Notably, our recent unpublished data indicate that MLC1 can
bind to a number of proteins with enzymatic activity, like kinases
and phosphatases (Table 1). Further studies are needed to under-
stand if MLC1 aﬀects TRPV4 function by acting as a docking site
for mechanical sensors. We recently demonstrated thatMLC1, by
modulating endosome acidity (see below), can inﬂuence TRPV4
traﬃcking favoring channel recycling versus degradation. We
cannot exclude that this eﬀect might mechanistically explain the
functional cooperation between MLC1 and TRPV4. Accordingly,
defects in calcium inﬂux during hyposmosis were also observed
in monocyte-derived macrophages from MLC patients (Petrini
et al., 2013).
Regulation of Cl− Channel Function
Among the processes involved in cell volume regulation chloride
currents are the object of intense research aimed at understand-
ing their involvement in the pathophysiology of MLC1. Chloride
is largely used as co-ion together with cations for electrical neu-
tralization during membrane ion ﬂuxes or as a counter-ion in
anion-exchange mechanisms. According toWalz (2002) the cyto-
plasmic chloride concentration in cultured astrocytes is around
40 mM. In vivo studies generated conﬂicting results. Depending
on the brain area, the intracellular chloride concentration ranged
between 36 and 46 mM (Smith et al., 1981), while a lower
concentration (6 mM) was found in unspeciﬁed glial cells in
slice preparations (Ballanyi et al., 1987). It seems that oligo-
dendrocytes have a lower intracellular chloride concentration
compared to astrocytes, in which the chloride intracellular con-
centration is actively kept around 40 mM. In astrocytes the
resulting reversal potential, which is more positive than the rest-
ing potential, gives rise to an eﬄux of the ion upon opening
of chloride channels during volume regulatory events (Walz,
2002).
Based on the available evidence, two diﬀerent chloride cur-
rents are potentially involved in MLC pathology. Defects in a
RVD-induced chloride current have been noted in rat astrocytes
following siRNA-mediated MLC1 downregulation and in MLC
patient-derived lymphoblasts (Ridder et al., 2011). Based on acti-
vation by hypotonic shock, ion selectivity, pharmacological sen-
sitivity, and outward rectifying property, the MLC1-dependent
current was identiﬁed as a volume regulated anion current
(VRAC). VRAC currents were also studied in astrocytes derived
from mlc1-null mice (Sirisi et al., 2014; Dubey et al., 2015). In
one of these studies, a VRAC current was identiﬁed as the Cl−
current sensitive to the VRAC inhibitor DCPIB (Sirisi et al.,
2014). The hypotonicity-induced VRAC current amplitude in
MLC1−/− astrocytes diﬀered slightly, but not signiﬁcantly, from
that recorded in WT astrocytes. However, the slightly smaller
VRAC current in MLC1−/− astrocytes was associated with more
pronounced vacuolation in brain tissue, consistent with a func-
tional decay of water/ion regulatory mechanisms (Sirisi et al.,
2014). In another study performed in astrocytes derived from
mlc1-null mice where the MLC1 gene has been replaced by the
green ﬂuorescent protein encoding sequence, astrocytes exhibited
a hypotonic challenge-induced Cl− current that was identiﬁed as
due to VRAC channels by cadmium insensitivity and tamoxifen
sensitivity (Dubey et al., 2015). Such a current had a lower ampli-
tude in astrocytes from MLC1−/− mice compared to those from
wild-type mice, indicating a VRAC current functional decay due
to MLC1 ablation. Consistent with the role of VRAC in RVD,
astrocytes from MLC1−/− mice reacted to a hypotonic challenge
with a slower RVD (Dubey et al., 2015). It is not clear whether dif-
ferences in the detection of the VRAC-induced chloride current
in the two mlc1-null mice models are due to technical problems
or to the inﬂuence of the genetic background (C57BL/6 versus
C57BL/6-129/Svj mixed genetic background). VRAC is not only
involved in the RVD, but also in pathological events like apoptotic
volume decrease, necrotic volume increase following lactacido-
sis and excitotoxicity (Okada et al., 2009; Pedersen et al., 2015).
Notably, VRAC is the target of several regulatory mechanisms
activated by osmotic cell swelling; among these, are EGFR acti-
vation and phosphorylation by PI3K, src and ERK (Pedersen
et al., 2015). Data supporting the possibility that MLC1 protein
itself acts as VRAC are not available. Recently, LRRC8A, a mem-
ber of the four-transmembrane protein family, was recognized
as a component of the VRAC channel in non-neural cells (Qiu
et al., 2014; Voss et al., 2014) and also in glial cells were LRRC8A
is an indispensable component of a permeability pathway that
mediates both swelling-activated and agonist-induced amino acid
release (Hyzinski-García et al., 2014). However, the relationship
between MLC1 and LRRC8A is still unknown.
Based on the presence of white matter vacuolation in
mice lacking ClC-2 (Blanz et al., 2007), this chloride chan-
nel was considered as potentially involved in MLC1 dis-
ease but no ClC-2 mutations were found in MLC patients
(Scheper et al., 2010). However, although initially in humans
ClC-2 loss- and gain-of function mutations were linked to
idiopathic generalized epilepsy with no apparent leukodys-
trophy (Haug et al., 2003), a recent study has revealed
that autosomal-recessive CLCN2 mutations cause a leukoen-
cephalopathy characterized by intramyelinic oedema (Depienne
et al., 2013).
ClC-2 channels are almost ubiquitous and their whole-cell
current is characterized by hyperpolarization-induced slow acti-
vation, slow deactivating tail currents at more positive potentials,
strong inward rectiﬁcation, and blockade by iodide but not by
classical Cl− channel inhibitors and tamoxifen (Jentsch et al.,
2002). In the ﬁrst in vitro study aimed at elucidating the role
of ClC-2 channels in MLC, no correlations between MLC1 pro-
tein and ClC-2 were found, MLC1 mRNA interference did not
change ClC-2 level, and the two proteins did not co-precipitate
(Jeworutzki et al., 2012). In the same study, attention was also
focused on GlialCAM, whose mutations were found in a sub-
population of MLC1 patients (López-Hernández et al., 2011a,b;
Capdevila-Nortes et al., 2013). Overexpression of GlialCAM
together with ClC-2 in Xenopus oocytes caused remark-
able changes of current features, such as ohmic conductance
instead of inward-rectiﬁcation, instantaneous activation instead
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of slow activation, and large increase in the current amplitude
(Jeworutzki et al., 2012). However, the current recorded in pri-
mary astrocytes and identiﬁed as carried by ClC-2 because of
lack of permeability to iodide and insensitivity to tamoxifen,
did not show the above features even if cultured astrocytes are
known to express GlialCAM. It cannot be ruled out that the
abrupt changes recorded in the heterologous system are the
result of GlialCAM protein overexpression (Jeworutzki et al.,
2012). A recent study performed in parallel in three diﬀerent
KO mouse models, MLC1−/−, GlialCAM−/− and ClC-2−/−,
addressed this point with a detailed analysis of whole-cell record-
ings from slice preparations (Hoegg-Beiler et al., 2014). As in
primary cortical astrocytes obtained from the previously charac-
terized mouse models (Sirisi et al., 2014), also in WT Bergman
glia, known to express GlialCAM, Cl− currents showed features
expected in the absence of GlialCAM (i.e., inward rectiﬁca-
tion and slow activation). Moreover, ablation of GlialCAM did
not result in the expected changes (i.e., large decrease of the
amplitude and stronger inward rectiﬁcation) and caused a mild
decrease of the current, compatible with the decrease in ClC-
2 expression observed in MLC1−/− and GlialCAM−/− mice
by immunohistochemistry. So far, the most likely interpretation
of these results is that MLC1 plays a role as a chaperone con-
tributing to the correct localization of ClC-2 proteins, but is not
involved in the modulation of the biophysical features of ClC-2
channel.
pH Regulation in the Endosomal Compartment
Both the V-ATPase and the Na, K-ATPase pumps are known
to regulate acidity of the endosomal compartment. Aiming at
investigating further the functional relationship between MLC1
and V-ATPase/Na, K-ATPase in the context of the MLC1-
associated macromolecular complex described in in vitro exper-
iments (Brignone et al., 2011, 2014), we studied the eﬀects of
MLC1 mutations on organelle pH.
Using a video-imaging approach with the pH sensitive dye
FITC-dextran, we found that in astrocytoma cells expressing
WT, but not mutated MLC1, early endosomes (i.e., EEA1+
and RAB5+) showed a higher pH compared to early endo-
somes from the parental U251 cells (Brignone et al., 2014).
This result is compatible with a possible role for MLC1 in
the modulation of V-ATPase and Na, K-ATPase function.
Being the early endosomal compartment a check-point sta-
tion where proteins are sorted toward recycling or degrada-
tion depending on further acidiﬁcation of the organelles, these
results suggest that MLC1 can inﬂuence the traﬃcking of pro-
teins co-localizing in the same early endosomes. Indeed, we
found that WT but not mutated MLC1 favored TRPV4 chan-
nel recycling (Brignone et al., 2014). These results are consis-
tent with a functional role of MLC1 in endosome pH regu-
lation, since recycling vesicles are characterized by a slightly
less acidic pH compared to vesicles sorted toward the lysoso-
mal degradative pathway (Grant and Donaldson, 2009; Scott
and Gruenberg, 2011). From a pathogenic point of view, it is
interesting to note that alterations in organelle pH regulation
induce endosome enlargement and formation of intracellular
vacuoles similar to those observed in MLC1 KO astrocytes
(Duarri et al., 2011) and that some neurodegenerative diseases
are characterized by abnormal giant endosomes (Gouras, 2013).
It has been hypothesized that disturbance of the endoplas-
mic compartment pH might be associated with the develop-
ment of autistic behavior resulting from an irregular arrange-
ment of membrane components like channels and transporters
in the plasmalemma of neurons and astrocytes during devel-
opment (Kondapalli et al., 2014). Notably, autism is part of
the symptomatology of MLC disease (López-Hernández et al.,
2011a).
MLC1 Functions: Astrocyte Specific
Ion Channel or Ion Channel Regulator?
The almost exclusive expression of MLC1 in astrocytes together
with the neuropathological alterations observed in MLC patients
and the results obtained in cellularmodels have led to hypothesize
a role for MLC1 in the regulation of ion/water ﬂuxes controlling
cell volume in speciﬁc astrocytic districts such as those facing
the brain barriers (blood–brain and cerebrospinal ﬂuid–brain
barriers).
Does MLC1 directly function as an ion/water permeation
site or as a transport protein? Ion channels herein referred to
are crucial for the transepithelial transport of salt and water,
the regulation of cellular volume and pH, the acidiﬁcation of
intracellular organelles, and chemical signaling. They may be
regulated by calcium, pH, phosphorylation, and lipids. Many
channels are oligomers of identical or homologous pore-forming
α subunits and assemble in complexes with β/γ subunits which
may be essential for their function or modulate their prop-
erties. Most of these features have been described for MLC1
(see above). Experimental studies revealed that several diﬀer-
ent (also redundant) mechanisms control MLC1 membrane
localization (protein–protein, protein–lipid interactions, post-
translational modiﬁcations) suggesting that a strict temporal and
spatial regulation of MLC1 is necessary in astrocytes. Although
at present conclusive results ruling out MLC1 direct involvement
in ion/water permeation/transport in astrocytes are missing, the
ensemble of the data collected so far converge to delineate a dual
role for MLC1 ranging from a chaperoning to a regulatory role of
functional events.
The observation that several of the pathological MLC1 muta-
tions cause a mislocalization of the protein together with that of
some of its functional interactors suggests a chaperoning-like role
of MLC1 in the correct assembly of those speciﬁc proteins. On
the other hand, the variety of events aﬀected byMLC1 ablation or
mutations, together with the recognition of several putative bind-
ing sites that could act as docking sites for regulatory enzymes,
prompt to consider its regulatory role in the complex scenario of
events taking place in speciﬁc intracellular domains and involving
water/ion movements and pH control.
Besides the exact deﬁnition of the multifaceted role played
by MLC1, the advent of MLC1 in animals developing myelin
prompts to consider in a phylogenetic perspective the importance
of this protein for the new needs of such a complex functional
structure comprising astrocytes, oligodendrocytes, and neurons.
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In MLC disease myelin degeneration is not attributable to direct-
myelin or oligodendrocyte protein alterations but to an indirect
eﬀect mediated by astrocytic dysfunction. Although at present
the molecular mechanisms causing myelin degeneration in MLC
disease are not known it is established that defects in astrocyte
maturation, astrocyte functional impairment causing accumu-
lation of toxic substrates, and/or failure of speciﬁc astrocyte-
mediated homeostatic pathways can aﬀect myelin formation and
maintenance leading to cystic or vacuolatingmyelin degeneration
(reviewed in Lanciotti et al., 2013 and references therein). Due to
the important role played by astrocytes in regulating oligoden-
drocyte progenitor cell proliferation, migration, and diﬀerentia-
tion during CNS development (Clemente et al., 2013), we cannot
exclude that dysfunctional astrocytes could aﬀect myelination
also by acting on oligodendrocyte development.
Concluding Remarks
Channelopathies are a diverse set of disorders associated with
defects in ion channel (and transporter) function that are mostly
linked with inherited mutations impairing the biophysical prop-
erties of the channels. The rapid progress made in molecular
genetics and electrophysiology has allowed to expand the ﬁeld
of channelopathies revealing that many disorders reﬂect dys-
functions in regulatory proteins that alter ion channel synthesis,
membrane traﬃcking and/or posttranslational modiﬁcations.
Moreover, associated proteins can deﬁne tissue/organ func-
tional speciﬁcity, making ion channels at a speciﬁc location more
susceptible to a pathological condition even if their expression
is not tissue-speciﬁc. This could be the case of MLC1 which
is highly and exclusively expressed by astrocytes in the CNS.
The results obtained so far demonstrate MLC1 involvement in
astrocyte volume control. Astrocytes not only undergo dramatic
volume changes as a result of the ionic dysregulation that occurs
in pathological conditions such as ischemia, trauma, and epilepsy
but also during neuronal activity in conjunction with extracellu-
lar K+ buﬀering (Florence et al., 2012 and references therein).
These volume regulatory mechanisms may thus be fundamen-
tal for the maintenance of the homeostatic conditions allowing
optimal CNS function. A deeper understanding of the struc-
ture and function of MLC1 protein and its relationship with
ion channels and ion channel-related proteins may contribute
not only to identify novel therapeutic approaches for the rare
MLC genetic disease, but may also provide insights into the
mechanisms underlying more common brain disorders such as
migraines, epilepsies, ischemia, and autism.
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